Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma(241 views visite) Storto G, Nardelli A, Pellegrino T, Perna F, De Falco T, Erra P, Ortosecco G, Castaldi E, Speranza A, Klain M, De Renzo A, Di Nuzzo C, Pace L, Rotoli B, Salvatore M
Keywords Parole chiave: Not available. Non disponibili.
Affiliations Affiliazioni: *** IBB - CNR ***
References Riferimenti: Not available. Non disponibili.
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Not available. Non disponibile.
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Assessment of Metabolic Response to Radioimmunotherapy (RIT) with Yttrium-90 (Y-90) Ibritumomab Tiuxetan in Patients with Relapsed or Refractory B-cell non-Hodgkin Lymphoma
Petraglia F, Singh AA, Carafa V, Nebbioso A, Conte M, Scisciola L, Valente S, Baldi A, Mandoli A, Petrizzi VB, Ingenito C, De Falco S, Cicatiello V, Apicella I, Janssen-megens EM, Kim B, Yi G, Logie C, Heath S, Ruvo M, Wierenga ATJ, Flicek P, Yaspo ML, Della Valle V, Bernard O, Tomassi S, Novellino E, Feoli A, Sbardella G, Gut I, Vellenga E, Stunnenberg HG, Mai A, Martens JHA, Altucci L * Combined HAT/EZH2 modulation leads to cancer-selective cell death(206 visite) Oncotarget (ISSN: 1949-2553electronic, 1949-2553linking), 2018 May 22; 9(39): 25630-25646. Impact Factor:5.008 DettagliEsporta in BibTeXEsporta in EndNote
Antonini A, Vitale C, Barone P, Cilia R, Righini A, Bonuccelli U, Abbruzzese G, Ramat S, Petrone A, Quatrale R, Marconi R, Ceravolo R, Stefani A, Lopiano L, Zappia M, Capus L, Morgante L, Tamma F, Tinazzi M, Colosimo C, Guerra UP, Valzania F, Fagioli G, Distefano A, Bagnato A, Feggi L, Anna S, Maria Teresa Rosaria De Cr, Nobili F, Mazzuca N, Baldari S, Eleopra R, Bestetti A, Benti R, Varrone A, Volterrani D, Massa R, Stocchi F, Schillaci O, Dore F, Zibetti M, Castellano G, Battista SG, Giorgetti G * The relationship between cerebral vascular disease and parkinsonism: The VADO study(422 visite) Parkinsonism Relat D (ISSN: 1353-8020, 1873-5126, 1873-5126electronic), 2012; 18(6): 775-780. Impact Factor:3.274 DettagliEsporta in BibTeXEsporta in EndNote
Testino G, Leone S, Fagoonee S, Del Bas JM, Rodriguez B, Puiggros F, Marine S, Rodriguez MA, Morina D, Armengol L, Caimari A, Arola L, Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-gentilucci U, Cavallo MG, Morini S, Nelson JE, Roth CL, Wilson LA, Yates KP, Aouizerat B, Morgan-stevenson V, Whalen E, Hoofnagle A, Mason M, Gersuk V, Yeh MM, Kowdley KV, Lee SM, Jun DW, Cho YK, Jang KS, Kucukazman M, Ata N, Dal K, Yeniova AO, Kefeli A, Basyigit S, Aktas B, Akin KO, Agladioglu K, Ure OS, Topal F, Nazligul Y, Beyan E, Ertugrul DT, Catena C, Cosma C, Camozzi V, Plebani M, Ermani M, Sechi LA, Fallo F, Goto Y, Ray MB, Mendenhall CL, French SW, Gartside PS Serum vitamin A deficiency and increased intrahepatic expression of cytokeratin antigen in alcoholic liver disease(433 visite) Hepatology (ISSN: 1827-1669electronic, 0026-4806linking), 1988 Sep; 83120693611123109(5): 1019-1026. Impact Factor:0.913 DettagliEsporta in BibTeXEsporta in EndNote
820 Records (638 escludendo Abstract e Conferenze). Impact factor totale: 2681.395 (2063.688 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 2789.919 (2104.473 escludendo Abstract e Conferenze).
Last modified by Ultima modifica di Marco Comerci on in data Sunday 12 July 2020, 13:15:02 241 views visite. Last view on Ultima visita in data Thursday 04 February 2021, 9:30:15